Experts are rapidly examining retatrutide, a promising medication from Eli Lilly, as a possible breakthrough in body management. Distinct from many earlier approaches, retatrutide is a double -action compound targeting both GLP-1 and GIP, hormones that impact satiety and glucose balance. Early r